Objective: Our previous study using the Goto-Kakizaki rat implicates that the adenylyl cyclase 3 (AC3) is a candidate gene for genetic study of metabolic disorders. The present study aimed to investigate the susceptibility of genetic variation of the AC3 gene in type 2 diabetes (T2D) patients and obese subjects. Subjects and methods: Variation screening in the putative promoter and validation of single nucleotide polymorphisms (SNPs) covering the AC3 gene were performed. In total, 630 Swedish men, including 243 T2D patients (BMI from 18.4 to 45.6 kg m À2 ), 199 obese subjects with normal glucose tolerance (NGT, BMIX30 kg m À2 ) and 188 control subjects (NGT, BMIp26 kg m À2 ), were genotyped. Results: A novel variant -17A/T in the promoter was identified, but no significant association of this polymorphism with T2D was found. SNPs rs2033655 C/T and rs1968482 A/G were found to be significantly associated with obesity when T2D patients had BMIX30 kg m À2 (P ¼ 0.003 and 0.005). The significance was borderline in T2D patients with BMIo30 kg m À2 (P ¼ 0.051 and 0.084) and disappeared in T2D patients with BMIp26 kg m À2 . Importantly, analysis in obese subjects with NGT demonstrated that these two polymorphisms were strongly associated with obesity per se (P ¼ 0.028 and 0.003). Furthermore, analyses for diplotypes (haplotypic genotypes) predicted an association with BMI in obese subjects.
Introduction
Type 2 diabetes (T2D) (OMIM: #125853) and obesity (OMIM: #601665) are complex metabolic disorders, and obesity is often associated with T2D.
1,2 T2D and obesity may have common genetic susceptibility and environmental factors, which are involved in development of the disorders. Identification of the susceptibility genes is therefore important for a better understanding of the pathogenesis of T2D and obesity.
Adenylyl cyclases (or adenylate cyclases, ACs) are enzymes that catalyze the synthesis of cyclic 3 0 5 0 -AMP (cAMP) from ATP. At least nine closely related isoforms of ACs have been cloned and characterized in mammals.
3 AC3 (OMIM:
600291), as a member of AC family, is expressed in pancreatic islets, brain, heart, kidney, liver, lung and skeletal muscle. The protein consists of two transmembrane regions M1 and M2, each containing six predicted membranespanning helices, and two cytoplasmic regions C1 and C2. 3 The Goto-Kakizaki (GK) rat exhibits a markedly reduced glucose-induced insulin release in vivo, and in the isolated perfused pancreas and isolated islets. [4] [5] [6] [7] A previous study from our laboratory demonstrated that the AC3 mRNA was overexpressed in the pancreatic islets of GK rat, which was caused by two point mutations at positions À28 A/G and À358 A/C of the promoter region. 8 The insulinotropic effect of forskolin in GK rat islets is associated with an enhanced cAMP generation and with overexpression of AC3 mRNA. 9 Moreover, liver adenylyl cyclase activity was increased in the membranes of male ob/ob mice in comparison to the lean control mice. 10 These findings suggest a role for the AC3 gene in the pathogenesis of T2D and obesity. As for the patients with T2D, obesity and metabolic syndrome, however, there is no reported study of genetic association with the AC3 gene.
In the present study, we investigated the association of T2D with AC3 genetic variation in Swedish men. We found that the AC3 gene may confer susceptibility to obesity in T2D patients. We further demonstrated that AC3 genetic variation is associated with obesity in Swedish male obese subjects with normal glucose tolerance (NGT). Clinical characteristics of all patients and subjects are summarized in Table 1 . Informed consent was given by all subjects and patients studied, and the studies were approved by the local ethical committee.
Materials and methods

Subjects
Variation screening
Genomic DNA was extracted from peripheral blood by using a Puregene DNA purification kit (Gentra, USA). Screening for variation in the putative promoter region of the AC3 gene was performed with a protocol of direct sequencing analysis. 
SNP selection and bioinformatics
The criteria for selection of SNPs was adjusted based upon allele frequency (at least 5%), function (non-synonymous, synonymous or intronic) and location of the polymorphisms. The AC3 gene has high homology with other ACs isoforms. For each SNP, the surrounding approximately 50 bp sequences in 5 0 -or 3 0 -direction were not only examined for repeats and duplicated sequences (http://repeatmasker. genome.washington.edu/cgi-bin/RepeatMasker) but also blasted for identical homology of the AC3 genomic sequences in the human genome (http://www.ncbi.nlm.nih.gov/blast). A total of 27 SNPs in the genomic region of the 3 0 -UTR of RBJ gene and the AC3 gene were selected from dbSNP (http:// www.ncbi.nlm.nih.gov/SNP/) for our study. To test whether SNPs were polymorphic in our population, each SNP was 
SNP genotyping
We used the high throughput SNP scoring techniques including dynamic allele-specific hybridization (DASH) (MCA System, ThermoHybaid, UK) and TaqMan (ABI 7300, Applied Biosystem, USA). To confirm our genotyping data, particular for those SNPs that were not in Hardy-Weinberg equilibrium (HWE), we have used another high-throughput genotyping method, that is pyrosequencing (PSQ96t, Pyrosequencing AB, Sweden) using the same primers as in DASH. The primers and probes designed for PCR-DASH and TaqMan genotyping assays are available upon request. 
Statistical analyses
Results
With a direct-sequencing analysis approach, we carried out variation screening for the putative promoter region of human AC3 gene and identified a novel SNP, that is -17A/T. We then genotyped 14 valid SNPs, including this novel polymorphism, in the clinical material. Table 2 represents information concerning studied SNPs in the AC3 gene and their major allele frequencies in the healthy Swedish men. Independent segregation of alleles for all studied SNPs in each group of the patients or subjects was tested and no departures from HWE were found (a ¼ 0.05).
Single marker association analysis for all studied SNPs was performed. The identified SNP -17A/T in the promoter region of the human AC3 gene had a relatively low frequency of allele A. The allele frequencies of this polymorphism in control subjects and T2D patients were 4 and 8%, respectively. The difference between these two frequencies was not statistically significant (P ¼ 0.076). From the other SNPs, however, we found that two SNPs, rs2033655 and rs1968482, had significant differences of allele frequencies when comparing control subjects and all T2D patients (P ¼ 0.004 and 0.008, respectively). For these two SNPs, heterozygous individuals did not confer a significant risk to homozygous non-risk allele carriers (P40.05 for each SNP), enabling acceptance of a recessive mode of inheritance. Analyses for genotype differences showed that both SNPs were associated with all T2D patients. In T2D patients, BMI varies from 18.4 to 45.6 kg m from these two polymorphisms. Frequencies of the haplotype H3 ¼ C-G in cases and controls were 1% or less. This haplotype was therefore excluded from the analysis. Table 4 shows the frequencies of the three common haplotypes. Haplotype frequencies in controls were significantly different from T2D and obese subjects. Diplotype association analyses with quantitative traits in T2D patients, obese and control subjects were performed (the diplotype H2/H2 was excluded in this analysis due to its lower frequency). Results revealed a significant association with BMI in obese subjects (P ¼ 0.004) as represented in Figure 1 . The results were same after adjusting for age (P ¼ 0.004). No statistically significant association of the diplotypes with BMI and other clinical features was detected in healthy control subjects and T2D patients.
Discussion
We have conducted a genetic association study for the AC3 gene in T2D patients and obese subjects in Swedish men. SNPs rs2033655 and rs1968482 are strongly associated with obese subjects with NGT and obese T2D patients (BMIX30 kg m
À2
). The association of these two polymorphisms with non-obese T2D patients (BMI p26 or o30 kg m À2 ), however, was found to be nonsignificant or of borderline significance. Moreover, we have attempted to detect association of the AC3 genetic polymorphisms with quantitative traits in the patients with T2D and obese subjects. No significant results from single marker association analyses with quantitative traits were observed. The analyses for diplotypes constructed with these two polymorphisms, however, predict a significant association with BMI in obese subjects. ).
Susceptibility of AC3 to T2D and obesity S Nordman et al SNPs rs2033655 and rs1968482 are, respectively, located in introns 1 and 2, which covers exon 2 of the AC3 gene. These two introns are large and the exon 2 encodes for the partial catalytic domain of AC3. Furthermore, there is a large LD block in the region from intron 1 to exon 2 and intron 2 (B67% of genomic region of the whole gene, see the release No. 22 of HapMap). This observation predicts that AC3 genetic variation may be important for the biological function of the gene. It has been amply demonstrated that AcsFcampFprotein kinase A axis is involved in regulation of both insulin release and lipolysis. Important incretin hormones such as glucagon-like peptide (GLP-1), gastric inhibitory polypeptide (GIP) and b-adrenergic (AR) agonists are known to stimulate insulin release by increasing synthesis of cAMP. [15] [16] [17] [18] In humans, the most important regulators of lipolysis are catecholamines, which stimulate mobilization of fat through b-adrenergic receptors and generation of cAMP, whereas a2-adrenergic receptors suppress cAMP generation and lipolysis. cAMP influences may be important in regulating pancreatic islet b-cell differentiation, growth and survival. 19 ACs 1, 3 and 8, are most abundantly expressed in the brain and islets, where the cells need an elevated cAMP level to respond to multiple stimuli. [20] [21] [22] AC3 may play an interactive role with GLP-1, GIP and AR in control of insulin release and lipolysis. Therefore, a comprehensive analysis of AC3 in regulation of signaling by GLP-1, GIP and AR is necessary in order to understand the cellular mechanisms behind the postulated influence of AC3 genetic variation on BMI and other related metabolic features in T2D and obesity.
In conclusion, the present study provides the first evidence that the AC3 gene polymorphisms are associated with obesity in Swedish men with and without diabetes. We are considering further investigation to understand whether AC3 genetic polymorphisms influence abnormal glucose regulation and insulin resistance in T2D and obesity. Haplotype frequencies were estimated using EH-plus program. P-values were calculated using a likelihood ratio test on three degrees of freedom. Susceptibility of AC3 to T2D and obesity S Nordman et al
BMI (kg/m
